Real-World Performance of the MiniMed 780G Advanced Hybrid Closed-Loop System in the Middle East, North Africa, and Türkiye Region
Authors' conclusion
MiniMed 780G system RWE data in the MENAT region showed a sustained glycemic control that achieved international target criteria across different age groups, countries, and climate extremes.
Study context
- Population
- MiniMed 780G automated insulin delivery (AID) system users in the Middle East, North Africa and Türkiye (MENAT), countries with >25 users; CareLink data as of July 01, 2024
- Participants
- 7,965 participants19 MENAT countries
- Outcome
- CGM-based glycaemic metrics, overall cohort
Methodological detailsreal-world evidence, CareLink personal data, multinational (19 MENAT countries)
- Real-world evidence
- CareLink personal data
- Multinational (19 MENAT countries)
Main finding
As reported in the abstract
- Glucose management index (GMI), mean ± SD
- 6.9 ± 0.7%
- Time in range (TIR), mean ± SD
- 71.7 ± 18.2%
- Time in tight range (TITR), mean ± SD
- 48.9 ± 19.4%
- TBR <70 mg/dL, mean ± SD
- 2.4 ± 3.9%
- TBR <54 mg/dL, mean ± SD
- 0.5 ± 1.7%
Observational data: associations, not effects.
Further findings
TIR and TITR in users with optimal settings (glucose target 100 mg/dL, active insulin time 2 h)
- TIR, mean ± SD
- 76.3 ± 16.4%
- TITR, mean ± SD
- 54.2 ± 18.8%
Subgroups (age groups, countries, seasons, weekday/weekend, day/night)
- Consistent results across age groups, countries, the four seasons, weekday/weekends and day/night
Longitudinal and pre- to post-AHCL initiation cohorts · 12 months
- Glycaemic improvements began after AHCL initiation and sustained for 12 months; TIR and TBR70 reached international targets in all months
Original publication
Real-World Performance of the MiniMed 780G Advanced Hybrid Closed-Loop System in the Middle East, North Africa, and Türkiye Region. Diabetes Technol Ther. Published 9 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →